Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 13 of 16
ALL Adult Consortium Trial: Adult ALL Trial
NCT00476190
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
NCT00459043
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
NCT00431210
Personal Patient Profile Prostate (P4) Randomized, Multisite Trial
NCT00692653
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
NCT00436072
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination
NCT00442130
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00402545
RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
NCT00409292
Skin Cancer Screening and Education at Beaches
NCT00894855
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
NCT00476476
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
NCT00601146
Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation
NCT00428233
Melatonin Versus Placebo in Breast Cancer
NCT01805089
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
NCT00880334
Rituximab for Prevention of Chronic GVHD
NCT00379587
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
NCT00394433
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT00422656
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
NCT00418093
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
NCT00422799
Exercise Intervention in Women With Metastatic Breast Cancer
NCT00405782
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
NCT00369226
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
NCT00476086
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
NCT00424515
Ph II CHOP+Velcade in Mediastinal LBCL
NCT00361621
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation
NCT00355407
A Pilot Weight Control Intervention at HPHC
NCT00644202
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
NCT00578149
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
NCT00330252
Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00358163
Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function
NCT00525460
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
NCT00322881
Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients
NCT00317603
Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer
NCT00880464
Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
NCT00282282
Rapamycin FOR Kidney Angiomyolipomas
NCT00126672
Pemetrexed in Patients With Advanced Neuroendocrine Tumors
NCT00424723
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
NCT00459186
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
NCT00250926
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
NCT00301093
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
NCT00268918
A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors
NCT00588107
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00165477
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
NCT00333190
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
NCT00230542
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
NCT00165295
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
NCT00130702
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
NCT00130689
Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer
NCT00139191
Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
NCT00165412
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.